Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.740
+0.380 (8.72%)
At close: Mar 4, 2026, 4:00 PM EST
4.660
-0.080 (-1.69%)
After-hours: Mar 4, 2026, 7:49 PM EST
Nuvation Bio Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Nuvation Bio stock have an average target of 11.22, with a low estimate of 7.00 and a high estimate of 17. The average target predicts an increase of 136.71% from the current stock price of 4.74.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nuvation Bio stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $10 → $7 | Hold | Maintains | $10 → $7 | +47.68% | Mar 3, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $12 → $13 | Buy | Maintains | $12 → $13 | +174.26% | Mar 3, 2026 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +132.07% | Feb 10, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $9 → $12 | Buy | Maintains | $9 → $12 | +153.16% | Jan 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $17 | Strong Buy | Maintains | $18 → $17 | +258.65% | Jan 12, 2026 |
Financial Forecast
Revenue This Year
177.86M
from 62.90M
Increased by 182.76%
Revenue Next Year
341.18M
from 177.86M
Increased by 91.83%
EPS This Year
-0.50
from -0.60
EPS Next Year
-0.07
from -0.50
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 226.1M | 424.6M | |||
| Avg | 177.9M | 341.2M | |||
| Low | 104.3M | 217.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 259.4% | 138.7% | |||
| Avg | 182.8% | 91.8% | |||
| Low | 65.8% | 22.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.25 | 0.23 | |||
| Avg | -0.50 | -0.07 | |||
| Low | -1.05 | -0.35 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.